WO1989000869A1 - Glaucoma drainage in the lacrimal system - Google Patents
Glaucoma drainage in the lacrimal system Download PDFInfo
- Publication number
- WO1989000869A1 WO1989000869A1 PCT/US1988/002694 US8802694W WO8900869A1 WO 1989000869 A1 WO1989000869 A1 WO 1989000869A1 US 8802694 W US8802694 W US 8802694W WO 8900869 A1 WO8900869 A1 WO 8900869A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- tube
- eye
- drainage system
- outlet end
- lacrimal
- Prior art date
Links
- 208000010412 Glaucoma Diseases 0.000 title claims abstract description 16
- 239000012530 fluid Substances 0.000 claims abstract description 32
- 210000002159 anterior chamber Anatomy 0.000 claims abstract description 28
- 238000000034 method Methods 0.000 claims abstract description 24
- 210000000795 conjunctiva Anatomy 0.000 claims description 7
- 210000003717 douglas' pouch Anatomy 0.000 claims description 5
- 239000011148 porous material Substances 0.000 claims description 5
- 239000002245 particle Substances 0.000 claims description 3
- 230000004410 intraocular pressure Effects 0.000 abstract description 6
- 210000001742 aqueous humor Anatomy 0.000 abstract description 5
- 239000007788 liquid Substances 0.000 abstract description 4
- 238000004891 communication Methods 0.000 abstract description 2
- 210000001508 eye Anatomy 0.000 description 37
- 238000001356 surgical procedure Methods 0.000 description 9
- 210000003786 sclera Anatomy 0.000 description 5
- 208000002352 blister Diseases 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 241000282414 Homo sapiens Species 0.000 description 3
- 210000004087 cornea Anatomy 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 240000008100 Brassica rapa Species 0.000 description 2
- 241001274216 Naso Species 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 210000004083 nasolacrimal duct Anatomy 0.000 description 2
- 230000037390 scarring Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- QCHFTSOMWOSFHM-WPRPVWTQSA-N (+)-Pilocarpine Chemical compound C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C QCHFTSOMWOSFHM-WPRPVWTQSA-N 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- WLRMANUAADYWEA-NWASOUNVSA-N (S)-timolol maleate Chemical compound OC(=O)\C=C/C(O)=O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 WLRMANUAADYWEA-NWASOUNVSA-N 0.000 description 1
- 241000272525 Anas platyrhynchos Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 241000223783 Glaucoma Species 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 241000428533 Rhis Species 0.000 description 1
- QCHFTSOMWOSFHM-UHFFFAOYSA-N SJ000285536 Natural products C1OC(=O)C(CC)C1CC1=CN=CN1C QCHFTSOMWOSFHM-UHFFFAOYSA-N 0.000 description 1
- 208000002847 Surgical Wound Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000004406 elevated intraocular pressure Effects 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 210000004561 lacrimal apparatus Anatomy 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 210000001328 optic nerve Anatomy 0.000 description 1
- 229960001416 pilocarpine Drugs 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 238000011176 pooling Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000000452 restraining effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 229920002379 silicone rubber Polymers 0.000 description 1
- 239000004945 silicone rubber Substances 0.000 description 1
- 206010041232 sneezing Diseases 0.000 description 1
- 229910052715 tantalum Inorganic materials 0.000 description 1
- GUVRBAGPIYLISA-UHFFFAOYSA-N tantalum atom Chemical compound [Ta] GUVRBAGPIYLISA-UHFFFAOYSA-N 0.000 description 1
- 210000001760 tenon capsule Anatomy 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229960005221 timolol maleate Drugs 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
- A61F9/007—Methods or devices for eye surgery
- A61F9/00781—Apparatus for modifying intraocular pressure, e.g. for glaucoma treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
- A61F9/007—Methods or devices for eye surgery
- A61F9/00772—Apparatus for restoration of tear ducts
Definitions
- This invention relates to the field of ophthal ⁇ mology, and particularly to devices and methods for conducting fluids within and about the eye and the lacrimal drainage system.
- Glaucoma is a disease characterized by elevated intraocular pressure which, if not checked, may lead to nerve damage and visual loss. Pressures in the range of from about 15 + 3mm Hg up to about 21mm Hg may be considered to be in the normal range for human beings, whereas pressures substantially above that range are considered abnormally high. If pressures in the higher range are maintained for substantial periods of time, damage to the optic nerve of the eye may occur, leading to a narrowing of the field of vision and eventually to blindness if not appropri ⁇ ately treated.
- glaucoma can be treated through the administration of certain medi ⁇ cines such as pilocarpine, epinephrine and timolol maleate, it is often necessary to surgically provide - for the release of intraocular pressure for those patients who do not respond to drug therapy or who continue to lose vision under therapy.
- certain medi ⁇ cines such as pilocarpine, epinephrine and timolol maleate
- the exterior end of a tube extending through the wall of the eye is provided with a pressure relief valve in the form of small slits made through the wall of the tube at its end.
- a pressure relief valve in the form of small slits made through the wall of the tube at its end.
- N.T. Mascati describes a different method of drainage in "A New Surgical Approach for the Control of a Class of Glaucomas", International Surgery, Vol. 47:10-15 (1967). Dr. Mascati tried inserting one end of a drainage tube into the anterior chamber of an eye and the other end of the tube into the nasolacrimal duct. This procedure met with -only limited success, and is not currently employed due, presumably, to problems in ocular pressure control, infections and related complications.
- the Mascati device had no means for controlling liquid flow such as a pressure relief valve there was no way (1) to prevent collapse cf the anrericr chamber of the eye and (2) to prevent reflux of fluid from the naso ⁇ lacrimal drainage system into the anterior chamber of the eye during sneezing or nose-blowing.
- the invention provides a device and method for relieving high intraocular pressures associated with glaucoma.
- the device includes a flexible tube having one end extendable into the anterior chamber of the eye and having its other end in communication with the lacrimal drainage system of the eye.
- One-way valve means are provided within the tube to restrain liquid flow within the tube to a direction toward the lacri ⁇ mal drainage system. Since the lacrimal drainage system is lined with epithelial cells and is a natural passageway for fluid flow,, the scarring from fibrous tissue usually associated with draining is avoided.
- the one-way valve means also prevents back flow of fluids from the lacrimal drainage system into the eye, thus avoiding ascension of infection into the eye.
- One embodiment of the ocular device has filter means carried by the tube for restraining particles from passing therethrough toward the anterior chamber of the eye to further protect the eye from infection.
- the method comprises the steps of inserting the one end of the tube into the anterior chamber of the eye, allowing aqueous humor to escape into the tube, and attaching the other tube end to the eye so that fluid will drain into the lacrimal drainage system.
- the outlet end of the tube may be inserted into-the canaliculi, conjunctival cul-de-sac, lacrimal sac, lacrimal duct, lacrimal passage, or nasal passage te ⁇ allow fluid flow outwardly from the tube into the passages of the nasolacrimal system.
- Another embodiment: of the invention desirably employs a air of one-way valves wirhin the rube. Both one-way valves permit fluid flow only from the anterior chamber into the lacrimal drainage system.
- One one-way valve desirably is positioned at or near the tube end (inlet end) that will be placed into the anterior chamber.
- the other one-way valve desirably is positioned at or near the tube end (outlet end) inserted into the lacrimal drainage system.
- Figure 1 is a front view of an eye showing a nasolacrimal drainage system and the device of this invention
- Figure 2 is a cross-section of an eye showing a tube implanted by the method of this invention
- Figure 3 is a top view of a device of this invention.
- Figure 4 is a cross-sectional view along the line A-A of the device of Figure 3.
- Figure 1 shows somewhat schematically the front of a human eye and the lacrimal drainage system.
- the lacrimal gland (not shown) continuously supplies the eye with lacrimal fluid or tears.
- the lacrimal fluid washes across the conjunctiva (11) and the cornea (16).
- Excess lacrimal fluid not retained by the eye is commonly drained to the nasal passages, the infer ⁇ ior nasal meatus (not shown) in particular.
- the excess fluid is drained through a network of passages that commences with the puncta that appears as a small papilla adjacent the inner canthus or. the inner corner of the eye.
- the fluid is collected in the lacrimal sac (23) by a number of canaliculi (20) connecting the puncta to the sac.
- the sac (23) is then drained through its extension, the naso ⁇ lacrimal duct (24) which passes into the inferior nasal eatus for this purpose.
- This network of passages is referred to herein as the lacrimal drainage system (25).
- a tube (30) has an inlet end portion (31) that is shaped to be inserted through a small incision made in the wall of the eye so that the end (31) is posi ⁇ tioned in the interior of the eye, preferably in the anterior chamber.
- the other outlet end (32) of the tube is shaped to be inserted through a small incision made in a portion of the lacrimal drainage system to be positioned therein.
- the tube (30), desirably is on the order of about 1 to about 8cm long and about 0. to about 1.5 mm in outer diameter.
- the end portions may be of a comparatively rigid material such as poly- methylmethacrylate or of a metal such as gold or other biologically acceptable materials, and the ends may be joined together by a more flexible length of, e.g. , silicone rubber tubing.
- the entire length of the tube (30) r including the end portions is preferably made of a flexible material such as silicone or poly ⁇ ethylene.
- FIG 2 a cross-section of the human eye is shown that includes the device of the invention implanted in the anterior chamber.
- the cornea is shown as (16), the iris as (17), the lens as (18) and the limbus as (19).
- the inlet tube end (31) extends into the anterior chamber (14) of the eye and the outlet tube end (32) is positioned in the conjunc- tival cul-de-sac to allow fluid to flow from the tube ⁇ into the lacrimal drainage system.
- the device may be secured to the sclera (15) by sutures (34) or other conventional means.
- the one-way valve (35) or valves used with this invention may be of any of the various types suitable for use in the quite miniature device of the inven ⁇ tion, and such valves often also function as pressure relief valves as well.
- the one-way valve employed in this method desirably is competent to prevent back flow of fluid even against increases of pressure such as those that may occur within the lacrimal drainage system when a person sneezes, blows his nose or sneezes when the nose is plugged, e.g., 50 mm Hg.
- the one-way valve preferably is also a pressure relief valve that is adapted to open when the pressure in the eye exceeds the pressure within the tube by a pre-set threshold pressure, e.g. by about 8-lOmm Hg.
- the pressure within the tube will be maintained at or near atmospheric pressure (about 760mm Hg) .
- the valve prevents collapse of the anterior chamber.
- the unidirectional flow of the fluid into the lacrimal drainage system prevents viruses and bacteria carried by fluids in the lacrimal drainage system from being carried upwardly into the interior of the patient's eye through the tube.
- the valves may be any of a variety of well known designs which need not be described in detail, but which might include by way of example well known "duck valves".
- the one-way valve (35) may function as a pressure relief valve, the edges of the valve flaps pressing against one another to restrain fluid flow until the pressure differential across the valve increases to a level sufficient to cause the flaps to separate slightly, permitting fluid to pass. Reversal of the pressure gradient, as when the patient- sneezes, causes the flaps to press more tightly., together, thus restricting flow in the opposite direction.
- the valve When a tube having only one valve is used, the valve is positioned near the inlet end of the tube. The valve is thus more effective as a pressure relief valve, and back flow of fluid pooling within the tube is prevented.
- the outlet end of the tube is desirably surgi ⁇ cally inserted into the eye adjacent to or in the lacrimal drainage system.
- the tube end may be inserted in the conjunctival cul-de sac, the inferior or superior canaliculi (20), the lacrimal sac (23), the lacrimal duct (24), the nasal passage or any of the nasolacrimal passages or the nose. Fluid flows from the anterior chamber (14) of the eye through the tube (30) and into the passages of the lacrimal drainage system (25) and ultimately into the nasopharnyx where, if it has not been absorbed, it is swallowed.
- the ocular device shown in Figures 3 and 4 includes a microporous filter (40) that restrains micro-organisms and other particles having a mean diameter greater than the pore size from passing therethrough toward the anterior chamber of the eye.
- the filter may be of any known type such as a milli- pore filter made by the Millipore Company of Bedford, Mass.
- the filter desirably has a nominal pore size in the range of 0.1 micron to 10 microns and preferably has a pore size in the range of 0.1 ro 0.3 micron.
- the filter may be carried within rhe tube or it may be carried at the outlet end of the tube enclosing the end.
- the filter may be bag—shaped and extend outwardly of the tube end.
- the - bag-shaped filter may comprise a pair of filter -sheets (41,42) joined at their peripheries ro define an interior space (43) communicating wirh rhe outler end of the tube.
- a rather large limbal based flap of conjunctiva (11) is opened with an incision of about 6 to 10 mm posterior to the limbus. Care should be taken to provide no tears or button-holing of the conjunctiva. If tears occur, they should be repaired.
- the episcleral tissue (13) should be cleared from the region of the limbus (19) back for a distance (i.e., 5-8 mm) and any bleeding controlled with gentle cautery.
- the posterior margin of the conjunctiva (11) will be lifted and Tenon's capsule (12) interrupted with combined blunt and sharp dissection until the bare sclera of the eye is visible.
- a partial thickness scleral flap is outlined, the flap desirably measuring 4-5 mm in width and approximately 4-6 mm in anterior- posterior length.
- the tube (30) should be positioned under the scleral flap and a small incision made into the anterior chamber (14) at the limbus (19). The tube end (31) will then be threaded into the anterior chamber (14) until it can be visualized through the clear cornea (16).
- the limbal incision may be closed about the tube (30) and if a flange (33) is attached to the tube, it may be secured to the bed of the sclera (15) with partial thickness scleral bites and through-and- through bites through the flange (33) with a suture.
- a false channel may be created surgically in the posterior lateral wall of the sac.
- the tube end (32) is then threaded through that channel into the sac (23) and if desired, into the nasolacrimal duct (24).
- the length of the tube (30) must be sufficient to permit slippage of the tube within the sac when the eyeball rotates without dislodging the tube.
- outlet end of the tube (32) is to be inserted into the canaliculi (20) it will desirably be threaded through the backside of the eyelid and then into the posterior wall of the canaliculus.
- the out ⁇ let end of the tube (32) may be attached to the eye so that it is positioned in the conjunctival cul-de-sac adjacent the lacrimal drainage system.
- outlet tube end (32) is inserted into the nasolacrimal system (25), it is fixed to the sur ⁇ face of the sclera (15) under the conjunctiva (11) in the episcleral space.
- the tube (30) may be fixed to the eye using any well known surgical method such as sutures or scleral tunnels (34).
Abstract
A device and method for allowing fluid to flow from the interior of the eye into the nasolacrimal drainage system (25) associated with the eye to relieve high intraocular pressure in the treatment of glaucoma. The method employs a flexible tube (30) having one end extendable into the anterior chamber (16) of the eye and having its other end in communication with the nasolacrimal drainage system (25) of the eye. A one-way valve (35) is provided within the tube to restrain liquid flow to a direction from the anterior chamber (16) of the eye toward the lacrimal drainage system (25). The method includes the steps of inserting one end (31) of the tube into the anterior chamber (16) of the eye and inserting the other end of the tube into a portion of the nasolacrimal drainage system (25); aqueous humor is permitted to escape into the tube at the anterior chamber end (31), and flows outwardly into the passages of the nasolacrimal system (25). One or more one-way valves (35) within the tube permit fluid flow only away from the anterior chamber.
Description
GLAUCOMA DRAINAGE IN THE LACRIMAL SYSTEM
FIELD OF THE INVENTION
This invention relates to the field of ophthal¬ mology, and particularly to devices and methods for conducting fluids within and about the eye and the lacrimal drainage system.
BACKGROUND OF THE INVENTION
Glaucoma is a disease characterized by elevated intraocular pressure which, if not checked, may lead to nerve damage and visual loss. Pressures in the range of from about 15 + 3mm Hg up to about 21mm Hg may be considered to be in the normal range for human beings, whereas pressures substantially above that range are considered abnormally high. If pressures in the higher range are maintained for substantial periods of time, damage to the optic nerve of the eye may occur, leading to a narrowing of the field of vision and eventually to blindness if not appropri¬ ately treated. Although in certain cases glaucoma can be treated through the administration of certain medi¬ cines such as pilocarpine, epinephrine and timolol maleate, it is often necessary to surgically provide - for the release of intraocular pressure for those patients who do not respond to drug therapy or who continue to lose vision under therapy.
Medical researchers have investigated a number of methods for the surgical release of intraocular pressure. Such surgery, in its simplest form, has
involved making a small, surgical incision into the anterior chamber at or near the limbus to provide means for releasing an overabundance of aqueous humor from the eye into an adjacent subconjunctival space and thus to lower the intraocular pressure. In a modification of this procedure, a hair or other wicking material is reported to have been placed in the incision to provide a continuous passageway for excess fluid to be discharged from the eye. Other researchers have implanted small tubes that extend through the eye wall at the limbus or scleral-corneal junction for the purpose of providing a channel through which aqueous humor can escape.
Such surgical procedures, although still used to some extent, are far from adequate. Healing of the subconjunctival drainage space frequently results in scarring, rendering the space non-absorbent of aqueous humor. When this occurs, no liquid flow through the eye wall occurs, and the intraocular pressure may hence rise to dangerous levels. An excellent account of the history of glaucoma surgery is found in Bick, "Use of Tantalum for Ocular Drainage", Archives of Ophthalmology, Vol. 42:373-388(1949).
In a recent device, the exterior end of a tube extending through the wall of the eye is provided with a pressure relief valve in the form of small slits made through the wall of the tube at its end. Refer¬ ence is made to Krupin, T«, et al, "Valve Implants in - Filtering Surgery" , Am. . Ophthmo1■ , Vol. 81:23.2-235 (1976) . It is reported that fairly close control over the pressure needed to open the valve may be ob¬ tained. If the exterior or distal end of the tube is inserted beneath a flap of conjunctiva or the like, of course, the valved tube is subject to the same draw¬ backs as the other rubes described above. Glaucoma
surgeons have discovered that when surgery fails it is usually because the "bleb", the subconjunctival drain¬ age space created by the surgeon, has become fibrosed, causing it to shrink and become nonabsorbing.
One device that has been somewhat successful in maintaining the fluid absorbency of the bleb during the healing process was described by Molteno in 1969. Molteno, "New Implant for Drainage in Glaucoma", British Journal of Ophthalmology, Vol. 53:161 (1969). Molteno described a device made from a "stellon" brand acrylic monomer. The device consisted of two parts—a flat plate fashioned to conform to the sclera and a gutter incorporated at the point where a drainage tube met the plate to assure an even spread of drainage into the bleb. In 1979, Molteno disclosed a new device that had a biconcave base plate and a long εilicone tube, which served the same function as the first device. Reference is made to Chapter 11 of Glaucoma Surgery by Luntz, M.H., Harrison, R. and Schenker, H.I. (1984) for a description of this device.
The drainage of fluid into spaces of the eye has been unsuccessful largely due to the problem of bleb formation. N.T. Mascati describes a different method of drainage in "A New Surgical Approach for the Control of a Class of Glaucomas", International Surgery, Vol. 47:10-15 (1967). Dr. Mascati tried inserting one end of a drainage tube into the anterior chamber of an eye and the other end of the tube into the nasolacrimal duct. This procedure met with -only limited success, and is not currently employed due, presumably, to problems in ocular pressure control, infections and related complications. Because the Mascati device had no means for controlling liquid flow such as a pressure relief valve there was no way (1) to prevent collapse cf the anrericr chamber of the
eye and (2) to prevent reflux of fluid from the naso¬ lacrimal drainage system into the anterior chamber of the eye during sneezing or nose-blowing.
BRIEF DESCRIPTION OF THE INVENTION
The invention provides a device and method for relieving high intraocular pressures associated with glaucoma. The device includes a flexible tube having one end extendable into the anterior chamber of the eye and having its other end in communication with the lacrimal drainage system of the eye. One-way valve means are provided within the tube to restrain liquid flow within the tube to a direction toward the lacri¬ mal drainage system. Since the lacrimal drainage system is lined with epithelial cells and is a natural passageway for fluid flow,, the scarring from fibrous tissue usually associated with draining is avoided. The one-way valve means also prevents back flow of fluids from the lacrimal drainage system into the eye, thus avoiding ascension of infection into the eye. One embodiment of the ocular device has filter means carried by the tube for restraining particles from passing therethrough toward the anterior chamber of the eye to further protect the eye from infection.
The method comprises the steps of inserting the one end of the tube into the anterior chamber of the eye, allowing aqueous humor to escape into the tube, and attaching the other tube end to the eye so that fluid will drain into the lacrimal drainage system. The outlet end of the tube may be inserted into-the canaliculi, conjunctival cul-de-sac, lacrimal sac, lacrimal duct, lacrimal passage, or nasal passage te¬ allow fluid flow outwardly from the tube into the passages of the nasolacrimal system.
Another embodiment: of the invention desirably employs a air of one-way valves wirhin the rube.
Both one-way valves permit fluid flow only from the anterior chamber into the lacrimal drainage system. One one-way valve desirably is positioned at or near the tube end (inlet end) that will be placed into the anterior chamber. The other one-way valve desirably is positioned at or near the tube end (outlet end) inserted into the lacrimal drainage system. BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1 is a front view of an eye showing a nasolacrimal drainage system and the device of this invention;
Figure 2 is a cross-section of an eye showing a tube implanted by the method of this invention;
Figure 3 is a top view of a device of this invention; and
Figure 4 is a cross-sectional view along the line A-A of the device of Figure 3.
DETAILED DESCRIPTION OF THE INVENTION
Figure 1 shows somewhat schematically the front of a human eye and the lacrimal drainage system. The lacrimal gland (not shown) continuously supplies the eye with lacrimal fluid or tears. The lacrimal fluid washes across the conjunctiva (11) and the cornea (16). Excess lacrimal fluid not retained by the eye is commonly drained to the nasal passages, the infer¬ ior nasal meatus (not shown) in particular. At times the excess fluid is drained through a network of passages that commences with the puncta that appears as a small papilla adjacent the inner canthus or. the inner corner of the eye. The fluid is collected in the lacrimal sac (23) by a number of canaliculi (20) connecting the puncta to the sac. The canaliculi run inferiorly then medially to the lacrimal sac. The sac (23) is then drained through its extension, the naso¬ lacrimal duct (24) which passes into the inferior
nasal eatus for this purpose. This network of passages is referred to herein as the lacrimal drainage system (25).
A tube (30) has an inlet end portion (31) that is shaped to be inserted through a small incision made in the wall of the eye so that the end (31) is posi¬ tioned in the interior of the eye, preferably in the anterior chamber. The other outlet end (32) of the tube is shaped to be inserted through a small incision made in a portion of the lacrimal drainage system to be positioned therein. The tube (30), desirably is on the order of about 1 to about 8cm long and about 0. to about 1.5 mm in outer diameter. The end portions may be of a comparatively rigid material such as poly- methylmethacrylate or of a metal such as gold or other biologically acceptable materials, and the ends may be joined together by a more flexible length of, e.g. , silicone rubber tubing. The entire length of the tube (30) r including the end portions, is preferably made of a flexible material such as silicone or poly¬ ethylene.
In Figure 2, a cross-section of the human eye is shown that includes the device of the invention implanted in the anterior chamber. In that figure the cornea is shown as (16), the iris as (17), the lens as (18) and the limbus as (19). The inlet tube end (31) extends into the anterior chamber (14) of the eye and the outlet tube end (32) is positioned in the conjunc- tival cul-de-sac to allow fluid to flow from the tube ■ into the lacrimal drainage system. The device may be secured to the sclera (15) by sutures (34) or other conventional means.
The one-way valve (35) or valves used with this invention may be of any of the various types suitable for use in the quite miniature device of the inven¬ tion, and such valves often also function as pressure
relief valves as well. The one-way valve employed in this method desirably is competent to prevent back flow of fluid even against increases of pressure such as those that may occur within the lacrimal drainage system when a person sneezes, blows his nose or sneezes when the nose is plugged, e.g., 50 mm Hg. The one-way valve preferably is also a pressure relief valve that is adapted to open when the pressure in the eye exceeds the pressure within the tube by a pre-set threshold pressure, e.g. by about 8-lOmm Hg. The pressure within the tube will be maintained at or near atmospheric pressure (about 760mm Hg) . In this way, the valve prevents collapse of the anterior chamber. The unidirectional flow of the fluid into the lacrimal drainage system prevents viruses and bacteria carried by fluids in the lacrimal drainage system from being carried upwardly into the interior of the patient's eye through the tube. The valves may be any of a variety of well known designs which need not be described in detail, but which might include by way of example well known "duck valves".
As explained above, the one-way valve (35) may function as a pressure relief valve, the edges of the valve flaps pressing against one another to restrain fluid flow until the pressure differential across the valve increases to a level sufficient to cause the flaps to separate slightly, permitting fluid to pass. Reversal of the pressure gradient, as when the patient- sneezes, causes the flaps to press more tightly., together, thus restricting flow in the opposite direction. When a tube having only one valve is used, the valve is positioned near the inlet end of the tube. The valve is thus more effective as a pressure relief valve, and back flow of fluid pooling within the tube is prevented. When two valves are used, it
is desirable to have one valve near the inler end and one near the outlet end of the tube.
The outlet end of the tube is desirably surgi¬ cally inserted into the eye adjacent to or in the lacrimal drainage system. The tube end may be inserted in the conjunctival cul-de sac, the inferior or superior canaliculi (20), the lacrimal sac (23), the lacrimal duct (24), the nasal passage or any of the nasolacrimal passages or the nose. Fluid flows from the anterior chamber (14) of the eye through the tube (30) and into the passages of the lacrimal drainage system (25) and ultimately into the nasopharnyx where, if it has not been absorbed, it is swallowed.
The ocular device shown in Figures 3 and 4 includes a microporous filter (40) that restrains micro-organisms and other particles having a mean diameter greater than the pore size from passing therethrough toward the anterior chamber of the eye. The filter may be of any known type such as a milli- pore filter made by the Millipore Company of Bedford, Mass. The filter desirably has a nominal pore size in the range of 0.1 micron to 10 microns and preferably has a pore size in the range of 0.1 ro 0.3 micron. The filter may be carried within rhe tube or it may be carried at the outlet end of the tube enclosing the end. As shown in figures 3 and 4 the filter may be bag—shaped and extend outwardly of the tube end. The - bag-shaped filter may comprise a pair of filter -sheets (41,42) joined at their peripheries ro define an interior space (43) communicating wirh rhe outler end of the tube.
One surgical technique used in practicing rhe method of rhis invention is described below. This description is included εolelv for illuεrrarive
purposes; the method may be practiced using any of the numerous known surgical techniques.
In the region to be operated upon, a rather large limbal based flap of conjunctiva (11) is opened with an incision of about 6 to 10 mm posterior to the limbus. Care should be taken to provide no tears or button-holing of the conjunctiva. If tears occur, they should be repaired. The episcleral tissue (13) should be cleared from the region of the limbus (19) back for a distance (i.e., 5-8 mm) and any bleeding controlled with gentle cautery. The posterior margin of the conjunctiva (11) will be lifted and Tenon's capsule (12) interrupted with combined blunt and sharp dissection until the bare sclera of the eye is visible.
Centered at the limbus (19) a partial thickness scleral flap is outlined, the flap desirably measuring 4-5 mm in width and approximately 4-6 mm in anterior- posterior length. The tube (30) should be positioned under the scleral flap and a small incision made into the anterior chamber (14) at the limbus (19). The tube end (31) will then be threaded into the anterior chamber (14) until it can be visualized through the clear cornea (16). After the tube end (31) is posi¬ tioned, the limbal incision may be closed about the tube (30) and if a flange (33) is attached to the tube, it may be secured to the bed of the sclera (15) with partial thickness scleral bites and through-and- through bites through the flange (33) with a suture. - If the outlet end (32) of the tube is to be inserted into the nasolacrimal sac (23), a false channel may be created surgically in the posterior lateral wall of the sac. The tube end (32) is then threaded through that channel into the sac (23) and if desired, into the nasolacrimal duct (24). The length of the tube (30) must be sufficient to permit slippage of the tube
within the sac when the eyeball rotates without dislodging the tube.
If the outlet end of the tube (32) is to be inserted into the canaliculi (20) it will desirably be threaded through the backside of the eyelid and then into the posterior wall of the canaliculus. The out¬ let end of the tube (32) may be attached to the eye so that it is positioned in the conjunctival cul-de-sac adjacent the lacrimal drainage system.
After the outlet tube end (32) is inserted into the nasolacrimal system (25), it is fixed to the sur¬ face of the sclera (15) under the conjunctiva (11) in the episcleral space. The tube (30) may be fixed to the eye using any well known surgical method such as sutures or scleral tunnels (34).
While a preferred embodiment of the present invention has been described, it should be understood that various changes, adaptations and modifications may be made therein without departing from the spirit of the invention and the scope of the appended claims.
Claims
1. A method for treating glaucoma in an eye having an anterior chamber and an associated lac¬ rimal drainage system, comprising the steps of pro¬ viding a tube having inlet and outlet ends and a one¬ way valve therebetween to allow fluid flow only toward the outlet end; surgically inserting the inlet end of the tube into an anterior chamber of the eye; and positioning and attaching the outlet end of the tube so that fluid will flow from the end into the lacrimal drainage system of the eye.
2. The method of claim 1 wherein the outlet end of the tube is surgically inserted into the lacrimal drainage system of the eye.
3. The method of claim 2 wherein the outlet end of the tube is inserted into the portion of the lacrimal drainage system that is an inferior canaliculus.
4. The method of claim 2 wherein the outlet end of the tube is inserted into the portion of the lacrimal drainage system that is a superior canaliculus.
5. The method of claim 2 wherein the outlet end of the tube is inserted into the portion of the lacrimal drainage system that is a lacrimal sac.
6. The method of claim 2 wherein the outlet end of the tube is inserted into the portion of the lacrimal drainage system that is a lacrimal duct. -
7. The method of claim 2 wherein the outlet end of the tube is inserted into the portion of the lacrimal drainage system that is a lacrimal passage.
8. The method of Claim 1 wherein the outlet end of the tube is attached in the conjunctiva! cul-de-sac adjacent the lacrimal drainage system.
9. A method for treating glaucoma in an eye having an anterior chamber and associated lacrimal drainage system, comprising the steps of providing a tube having inlet and outlet ends and a pair of one-way valves therebetween permitting fluid flow only toward the outlet end; surgically inserting the inlet end of the tube into the anterior chamber of the eye; and surgically positioning and attaching the outlet end of the tube to the eye so that fluid will flow into the lacrimal drainage system.
10. An ocular device for glaucoma treat¬ ment comprising a flexible tube having inlet and out¬ let ends, shaped to be inserted into the anterior chamber of an eye and the lacrimal drainage system of the eye respectively, and a one-way valve positioned within the tube between the inlet and outlet ends to allow fluid flow only toward the outlet end.
11. The device of Claim 9 wherein the one-way valve is positioned proximal to the inlet end of the tube.
12. An ocular device for glaucoma treat¬ ment comprising a flexible tube having inlet and out¬ let ends, shaped to be inserted into the anterior chamber and the lacrimal drainage system of an eye, respectively, and at least two one-way valves posi¬ tioned within the tube between the inlet and outlet end to allow fluid flow only toward the outlet end.
13. The device of Claim 12 wherein one one-way valve is positioned proximal to the inlet end of the tube and. another one-way valve is positioned proximal to the outlet end of the tube.
1 . An ocular device for glaucoma treat¬ ment comprising a tube having inlet and outlet ends shaped to be inserted into the anterior chamber and rhe lacrimal drainage system of the eye, reεpecriveiy;
a one-way valve positioned within the tube between the inlet and outlet ends to allow fluid flow only toward the outlet end; and a microporous filter carried by the tube to restrain particles greater than the pore size from passing therethrough toward the inlet end.
15. The device of claim 14 wherein the filter is bag-shaped and encloses the outlet tube end, the filter extending outwardly of the tube beyond said outlet end and defining a space between two inner walls communicating with the outlet end.
16. The device of claim 15 in which the filter comprises a pair of filter sheets joined at their peripheries to define an interior space communicating with the outlet tube end.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US8283787A | 1987-08-06 | 1987-08-06 | |
US082,837 | 1987-08-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1989000869A1 true WO1989000869A1 (en) | 1989-02-09 |
Family
ID=22173766
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1988/002694 WO1989000869A1 (en) | 1987-08-06 | 1988-08-08 | Glaucoma drainage in the lacrimal system |
Country Status (3)
Country | Link |
---|---|
AU (1) | AU2308988A (en) |
CA (1) | CA1295907C (en) |
WO (1) | WO1989000869A1 (en) |
Cited By (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001078631A3 (en) * | 2000-04-14 | 2002-04-18 | Glaukos Corp | Apparatus and method for treating glaucoma |
US6533768B1 (en) | 2000-04-14 | 2003-03-18 | The Regents Of The University Of California | Device for glaucoma treatment and methods thereof |
US6666841B2 (en) | 2001-05-02 | 2003-12-23 | Glaukos Corporation | Bifurcatable trabecular shunt for glaucoma treatment |
WO2004060219A1 (en) * | 2002-12-27 | 2004-07-22 | Japan Science And Technology Agency | Aqueous humor drainage implant for treating glaucoma |
US7094225B2 (en) | 2001-05-03 | 2006-08-22 | Glaukos Corporation | Medical device and methods of use of glaucoma treatment |
US7135009B2 (en) | 2001-04-07 | 2006-11-14 | Glaukos Corporation | Glaucoma stent and methods thereof for glaucoma treatment |
US7331984B2 (en) | 2001-08-28 | 2008-02-19 | Glaukos Corporation | Glaucoma stent for treating glaucoma and methods of use |
US7811268B2 (en) | 2005-02-21 | 2010-10-12 | Artom S.A. | Device for draining aqueous humor in cases of glaucoma |
US7879001B2 (en) | 2002-04-08 | 2011-02-01 | Glaukos Corporation | Devices and methods for treatment of ocular disorders |
US7951155B2 (en) | 2002-03-15 | 2011-05-31 | Glaukos Corporation | Combined treatment for cataract and glaucoma treatment |
US8118768B2 (en) | 2001-04-07 | 2012-02-21 | Dose Medical Corporation | Drug eluting ocular implant with anchor and methods thereof |
US8142364B2 (en) | 2001-05-02 | 2012-03-27 | Dose Medical Corporation | Method of monitoring intraocular pressure and treating an ocular disorder |
US8348877B2 (en) | 2000-04-14 | 2013-01-08 | Dose Medical Corporation | Ocular implant with therapeutic agents and methods thereof |
US8506515B2 (en) | 2006-11-10 | 2013-08-13 | Glaukos Corporation | Uveoscleral shunt and methods for implanting same |
US8771217B2 (en) | 1999-04-26 | 2014-07-08 | Glaukos Corporation | Shunt device and method for treating ocular disorders |
US8945038B2 (en) | 2003-05-05 | 2015-02-03 | Transcend Medical, Inc. | Internal shunt and method for treating glaucoma |
US9084662B2 (en) | 2006-01-17 | 2015-07-21 | Transcend Medical, Inc. | Drug delivery treatment device |
US9089392B2 (en) | 2009-12-23 | 2015-07-28 | Transcend Medical, Inc. | Drug delivery devices and methods |
US9155656B2 (en) | 2012-04-24 | 2015-10-13 | Transcend Medical, Inc. | Delivery system for ocular implant |
US9220632B2 (en) | 2002-03-07 | 2015-12-29 | Glaukos Corporation | Fluid infusion methods for ocular disorder treatment |
US9301875B2 (en) | 2002-04-08 | 2016-04-05 | Glaukos Corporation | Ocular disorder treatment implants with multiple opening |
US9351873B2 (en) | 2003-11-14 | 2016-05-31 | Transcend Medical, Inc. | Ocular pressure regulation |
US9398977B2 (en) | 2006-01-17 | 2016-07-26 | Transcend Medical, Inc. | Glaucoma treatment device |
US9480598B2 (en) | 2012-09-17 | 2016-11-01 | Novartis Ag | Expanding ocular implant devices and methods |
US9585789B2 (en) | 2007-07-17 | 2017-03-07 | Novartis Ag | Ocular implant with hydrogel expansion capabilities |
US9592151B2 (en) | 2013-03-15 | 2017-03-14 | Glaukos Corporation | Systems and methods for delivering an ocular implant to the suprachoroidal space within an eye |
US9730638B2 (en) | 2013-03-13 | 2017-08-15 | Glaukos Corporation | Intraocular physiological sensor |
US9763829B2 (en) | 2012-11-14 | 2017-09-19 | Novartis Ag | Flow promoting ocular implant |
US9763828B2 (en) | 2009-01-28 | 2017-09-19 | Novartis Ag | Ocular implant with stiffness qualities, methods of implantation and system |
US9987163B2 (en) | 2013-04-16 | 2018-06-05 | Novartis Ag | Device for dispensing intraocular substances |
US10016301B2 (en) | 2008-06-25 | 2018-07-10 | Novartis Ag | Ocular implant with shape change capabilities |
US10085633B2 (en) | 2012-04-19 | 2018-10-02 | Novartis Ag | Direct visualization system for glaucoma treatment |
US10271989B2 (en) | 2012-03-26 | 2019-04-30 | Glaukos Corporation | System and method for delivering multiple ocular implants |
US10517759B2 (en) | 2013-03-15 | 2019-12-31 | Glaukos Corporation | Glaucoma stent and methods thereof for glaucoma treatment |
CN111449834A (en) * | 2020-04-15 | 2020-07-28 | 贵州省人民医院 | Lacrimal passage drainage device for lacrimal duct embolism and drainage method thereof |
US10959941B2 (en) | 2014-05-29 | 2021-03-30 | Glaukos Corporation | Implants with controlled drug delivery features and methods of using same |
US11116625B2 (en) | 2017-09-28 | 2021-09-14 | Glaukos Corporation | Apparatus and method for controlling placement of intraocular implants |
US11363951B2 (en) | 2011-09-13 | 2022-06-21 | Glaukos Corporation | Intraocular physiological sensor |
US11925578B2 (en) | 2015-09-02 | 2024-03-12 | Glaukos Corporation | Drug delivery implants with bi-directional delivery capacity |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3788327A (en) * | 1971-03-30 | 1974-01-29 | H Donowitz | Surgical implant device |
US4402681A (en) * | 1980-08-23 | 1983-09-06 | Haas Joseph S | Artificial implant valve for the regulation of intraocular pressure |
US4604087A (en) * | 1985-02-26 | 1986-08-05 | Joseph Neil H | Aqueous humor drainage device |
-
1988
- 1988-08-08 AU AU23089/88A patent/AU2308988A/en not_active Abandoned
- 1988-08-08 WO PCT/US1988/002694 patent/WO1989000869A1/en unknown
- 1988-08-08 CA CA000574099A patent/CA1295907C/en not_active Expired - Lifetime
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3788327A (en) * | 1971-03-30 | 1974-01-29 | H Donowitz | Surgical implant device |
US4402681A (en) * | 1980-08-23 | 1983-09-06 | Haas Joseph S | Artificial implant valve for the regulation of intraocular pressure |
US4604087A (en) * | 1985-02-26 | 1986-08-05 | Joseph Neil H | Aqueous humor drainage device |
Non-Patent Citations (1)
Title |
---|
INTERNATIONAL SURGERY, Vol. 47, No. 1, January 1967, NAUMANN T. MASCATI, "A New Surgical Approach for the Control of a Class of Glaucomas", (Note pages 10-15). * |
Cited By (91)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2260804B1 (en) | 1999-04-26 | 2016-10-19 | Glaukos Corporation | Trabeculotomy device for treating glaucoma |
US10568762B2 (en) | 1999-04-26 | 2020-02-25 | Glaukos Corporation | Stent for treating ocular disorders |
EP2260804B2 (en) † | 1999-04-26 | 2022-03-02 | Glaukos Corporation | Trabeculotomy device for treating glaucoma |
US8771217B2 (en) | 1999-04-26 | 2014-07-08 | Glaukos Corporation | Shunt device and method for treating ocular disorders |
US9492320B2 (en) | 1999-04-26 | 2016-11-15 | Glaukos Corporation | Shunt device and method for treating ocular disorders |
US10492950B2 (en) | 1999-04-26 | 2019-12-03 | Glaukos Corporation | Shunt device and method for treating ocular disorders |
US9827143B2 (en) | 1999-04-26 | 2017-11-28 | Glaukos Corporation | Shunt device and method for treating ocular disorders |
US10485702B2 (en) | 2000-04-14 | 2019-11-26 | Glaukos Corporation | System and method for treating an ocular disorder |
WO2001078631A3 (en) * | 2000-04-14 | 2002-04-18 | Glaukos Corp | Apparatus and method for treating glaucoma |
US6533768B1 (en) | 2000-04-14 | 2003-03-18 | The Regents Of The University Of California | Device for glaucoma treatment and methods thereof |
US9789001B2 (en) | 2000-04-14 | 2017-10-17 | Dose Medical Corporation | Ocular implant with therapeutic agents and methods thereof |
US9993368B2 (en) | 2000-04-14 | 2018-06-12 | Glaukos Corporation | System and method for treating an ocular disorder |
US8348877B2 (en) | 2000-04-14 | 2013-01-08 | Dose Medical Corporation | Ocular implant with therapeutic agents and methods thereof |
US9066782B2 (en) | 2000-04-14 | 2015-06-30 | Dose Medical Corporation | Ocular implant with therapeutic agents and methods thereof |
US8814820B2 (en) | 2000-04-14 | 2014-08-26 | Glaukos Corporation | Ocular implant with therapeutic agent and methods thereof |
US6736791B1 (en) | 2000-04-14 | 2004-05-18 | Glaukos Corporation | Glaucoma treatment device |
US10406029B2 (en) | 2001-04-07 | 2019-09-10 | Glaukos Corporation | Ocular system with anchoring implant and therapeutic agent |
US10828473B2 (en) | 2001-04-07 | 2020-11-10 | Glaukos Corporation | Ocular implant delivery system and methods thereof |
US7135009B2 (en) | 2001-04-07 | 2006-11-14 | Glaukos Corporation | Glaucoma stent and methods thereof for glaucoma treatment |
US8118768B2 (en) | 2001-04-07 | 2012-02-21 | Dose Medical Corporation | Drug eluting ocular implant with anchor and methods thereof |
US7857782B2 (en) | 2001-04-07 | 2010-12-28 | Glaukos Corporation | Ocular implant delivery system and method thereof |
US8579846B2 (en) | 2001-04-07 | 2013-11-12 | Glaukos Corporation | Ocular implant systems |
US8075511B2 (en) | 2001-04-07 | 2011-12-13 | Glaukos Corporation | System for treating ocular disorders and methods thereof |
US8062244B2 (en) | 2001-04-07 | 2011-11-22 | Glaukos Corporation | Self-trephining implant and methods thereof for treatment of ocular disorders |
US9572963B2 (en) | 2001-04-07 | 2017-02-21 | Glaukos Corporation | Ocular disorder treatment methods and systems |
US9987472B2 (en) | 2001-04-07 | 2018-06-05 | Glaukos Corporation | Ocular implant delivery systems |
US9155654B2 (en) | 2001-04-07 | 2015-10-13 | Glaukos Corporation | Ocular system with anchoring implant and therapeutic agent |
US6666841B2 (en) | 2001-05-02 | 2003-12-23 | Glaukos Corporation | Bifurcatable trabecular shunt for glaucoma treatment |
US8142364B2 (en) | 2001-05-02 | 2012-03-27 | Dose Medical Corporation | Method of monitoring intraocular pressure and treating an ocular disorder |
US7094225B2 (en) | 2001-05-03 | 2006-08-22 | Glaukos Corporation | Medical device and methods of use of glaucoma treatment |
US8337445B2 (en) | 2001-05-03 | 2012-12-25 | Glaukos Corporation | Ocular implant with double anchor mechanism |
US7273475B2 (en) | 2001-05-03 | 2007-09-25 | Glaukos Corporation | Medical device and methods of use for glaucoma treatment |
US10285856B2 (en) | 2001-08-28 | 2019-05-14 | Glaukos Corporation | Implant delivery system and methods thereof for treating ocular disorders |
US7331984B2 (en) | 2001-08-28 | 2008-02-19 | Glaukos Corporation | Glaucoma stent for treating glaucoma and methods of use |
US9561131B2 (en) | 2001-08-28 | 2017-02-07 | Glaukos Corporation | Implant delivery system and methods thereof for treating ocular disorders |
US7879079B2 (en) | 2001-08-28 | 2011-02-01 | Glaukos Corporation | Implant delivery system and methods thereof for treating ocular disorders |
US9220632B2 (en) | 2002-03-07 | 2015-12-29 | Glaukos Corporation | Fluid infusion methods for ocular disorder treatment |
US7951155B2 (en) | 2002-03-15 | 2011-05-31 | Glaukos Corporation | Combined treatment for cataract and glaucoma treatment |
US8882781B2 (en) | 2002-03-15 | 2014-11-11 | Glaukos Corporation | Combined treatment for cataract and glaucoma treatment |
US9301875B2 (en) | 2002-04-08 | 2016-04-05 | Glaukos Corporation | Ocular disorder treatment implants with multiple opening |
US7879001B2 (en) | 2002-04-08 | 2011-02-01 | Glaukos Corporation | Devices and methods for treatment of ocular disorders |
US10485701B2 (en) | 2002-04-08 | 2019-11-26 | Glaukos Corporation | Devices and methods for glaucoma treatment |
US9597230B2 (en) | 2002-04-08 | 2017-03-21 | Glaukos Corporation | Devices and methods for glaucoma treatment |
WO2004060219A1 (en) * | 2002-12-27 | 2004-07-22 | Japan Science And Technology Agency | Aqueous humor drainage implant for treating glaucoma |
US8945038B2 (en) | 2003-05-05 | 2015-02-03 | Transcend Medical, Inc. | Internal shunt and method for treating glaucoma |
US9844462B2 (en) | 2003-05-05 | 2017-12-19 | Novartis Ag | Internal shunt and method for treating glaucoma |
US9351873B2 (en) | 2003-11-14 | 2016-05-31 | Transcend Medical, Inc. | Ocular pressure regulation |
US10226380B2 (en) | 2003-11-14 | 2019-03-12 | Novartis Ag | Ocular pressure regulation |
US7811268B2 (en) | 2005-02-21 | 2010-10-12 | Artom S.A. | Device for draining aqueous humor in cases of glaucoma |
US9398977B2 (en) | 2006-01-17 | 2016-07-26 | Transcend Medical, Inc. | Glaucoma treatment device |
US10905590B2 (en) | 2006-01-17 | 2021-02-02 | Alcon Inc. | Glaucoma treatment device |
US9084662B2 (en) | 2006-01-17 | 2015-07-21 | Transcend Medical, Inc. | Drug delivery treatment device |
US9789000B2 (en) | 2006-01-17 | 2017-10-17 | Novartis Ag | Glaucoma treatment device |
US9668917B2 (en) | 2006-01-17 | 2017-06-06 | Novartis Ag | Drug delivery treatment device |
US11786402B2 (en) | 2006-01-17 | 2023-10-17 | Alcon Inc. | Glaucoma treatment device |
US9421130B2 (en) | 2006-01-17 | 2016-08-23 | Novartis Ag. | Glaucoma treatment device |
US10828195B2 (en) | 2006-11-10 | 2020-11-10 | Glaukos Corporation | Uveoscleral shunt and methods for implanting same |
US8506515B2 (en) | 2006-11-10 | 2013-08-13 | Glaukos Corporation | Uveoscleral shunt and methods for implanting same |
US9962290B2 (en) | 2006-11-10 | 2018-05-08 | Glaukos Corporation | Uveoscleral shunt and methods for implanting same |
US9585789B2 (en) | 2007-07-17 | 2017-03-07 | Novartis Ag | Ocular implant with hydrogel expansion capabilities |
US10016301B2 (en) | 2008-06-25 | 2018-07-10 | Novartis Ag | Ocular implant with shape change capabilities |
US10531983B2 (en) | 2009-01-28 | 2020-01-14 | Novartis Ag | Ocular implant with stiffness qualities, methods of implantation and system |
US11839571B2 (en) | 2009-01-28 | 2023-12-12 | Alcon Inc. | Ocular implant with stiffness qualities, methods of implantation and system |
US11344448B2 (en) | 2009-01-28 | 2022-05-31 | Alcon Inc. | Ocular implant with stiffness qualities, methods of implantation and system |
US9763828B2 (en) | 2009-01-28 | 2017-09-19 | Novartis Ag | Ocular implant with stiffness qualities, methods of implantation and system |
US9089392B2 (en) | 2009-12-23 | 2015-07-28 | Transcend Medical, Inc. | Drug delivery devices and methods |
US9549846B2 (en) | 2009-12-23 | 2017-01-24 | Novartis Ag | Drug delivery devices and methods |
US11363951B2 (en) | 2011-09-13 | 2022-06-21 | Glaukos Corporation | Intraocular physiological sensor |
US11197780B2 (en) | 2012-03-26 | 2021-12-14 | Glaukos Corporation | System and method for delivering multiple ocular implants |
US10271989B2 (en) | 2012-03-26 | 2019-04-30 | Glaukos Corporation | System and method for delivering multiple ocular implants |
US10085633B2 (en) | 2012-04-19 | 2018-10-02 | Novartis Ag | Direct visualization system for glaucoma treatment |
US9155656B2 (en) | 2012-04-24 | 2015-10-13 | Transcend Medical, Inc. | Delivery system for ocular implant |
US9241832B2 (en) | 2012-04-24 | 2016-01-26 | Transcend Medical, Inc. | Delivery system for ocular implant |
US9907697B2 (en) | 2012-04-24 | 2018-03-06 | Novartis Ag | Delivery system for ocular implant |
US10912676B2 (en) | 2012-04-24 | 2021-02-09 | Alcon Inc. | Delivery system for ocular implant |
US9480598B2 (en) | 2012-09-17 | 2016-11-01 | Novartis Ag | Expanding ocular implant devices and methods |
US9763829B2 (en) | 2012-11-14 | 2017-09-19 | Novartis Ag | Flow promoting ocular implant |
US10849558B2 (en) | 2013-03-13 | 2020-12-01 | Glaukos Corporation | Intraocular physiological sensor |
US9730638B2 (en) | 2013-03-13 | 2017-08-15 | Glaukos Corporation | Intraocular physiological sensor |
US10517759B2 (en) | 2013-03-15 | 2019-12-31 | Glaukos Corporation | Glaucoma stent and methods thereof for glaucoma treatment |
US10285853B2 (en) | 2013-03-15 | 2019-05-14 | Glaukos Corporation | Systems and methods for delivering an ocular implant to the suprachoroidal space within an eye |
US10188551B2 (en) | 2013-03-15 | 2019-01-29 | Glaukos Corporation | Systems and methods for delivering an ocular implant to the suprachoroidal space within an eye |
US11523938B2 (en) | 2013-03-15 | 2022-12-13 | Glaukos Corporation | Systems and methods for delivering an ocular implant to the suprachoroidal space within an eye |
US11559430B2 (en) | 2013-03-15 | 2023-01-24 | Glaukos Corporation | Glaucoma stent and methods thereof for glaucoma treatment |
US9592151B2 (en) | 2013-03-15 | 2017-03-14 | Glaukos Corporation | Systems and methods for delivering an ocular implant to the suprachoroidal space within an eye |
US9987163B2 (en) | 2013-04-16 | 2018-06-05 | Novartis Ag | Device for dispensing intraocular substances |
US10959941B2 (en) | 2014-05-29 | 2021-03-30 | Glaukos Corporation | Implants with controlled drug delivery features and methods of using same |
US11925578B2 (en) | 2015-09-02 | 2024-03-12 | Glaukos Corporation | Drug delivery implants with bi-directional delivery capacity |
US11116625B2 (en) | 2017-09-28 | 2021-09-14 | Glaukos Corporation | Apparatus and method for controlling placement of intraocular implants |
CN111449834B (en) * | 2020-04-15 | 2022-03-01 | 贵州省人民医院 | Lacrimal passage drainage device for lacrimal duct embolism and drainage method thereof |
CN111449834A (en) * | 2020-04-15 | 2020-07-28 | 贵州省人民医院 | Lacrimal passage drainage device for lacrimal duct embolism and drainage method thereof |
Also Published As
Publication number | Publication date |
---|---|
CA1295907C (en) | 1992-02-18 |
AU2308988A (en) | 1989-03-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4886488A (en) | Glaucoma drainage the lacrimal system and method | |
CA1295907C (en) | Glaucoma drainage in the lacrimal system | |
US10485702B2 (en) | System and method for treating an ocular disorder | |
EP0532654B1 (en) | Glaucoma implant | |
US4729761A (en) | Tissue-implantable, fluid-dissipating device | |
EP0228185B1 (en) | Tissue-implantable fluid-dissipating device | |
US5397300A (en) | Glaucoma implant | |
AU2001245698B2 (en) | Device for glaucoma treatment and methods thereof | |
US5433701A (en) | Apparatus for reducing ocular pressure | |
US20030236483A1 (en) | Dual drainage ocular shunt for glaucoma | |
EP2521517B1 (en) | An ophthalmic surgical device | |
AU2001245698A1 (en) | Device for glaucoma treatment and methods thereof | |
JP2002541976A (en) | Stent device and method for treating glaucoma | |
WO2002036052A1 (en) | Glaucoma treatment device | |
JP2017519592A (en) | Drainage device for glaucoma intraocular pressure control | |
WO1993020783A1 (en) | Glaucoma implant | |
WO2007006466A1 (en) | Device for the treatment of glaucoma |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU JP |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE FR GB IT LU NL SE |